2835 studies found for:    cyclophosphamide
Show Display Options
Rank Status Study
1 Recruiting Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Condition: Hematologic Malignancies
Intervention: Drug: Cyclophosphamide
2 Active, not recruiting Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Condition: HIV
Intervention: Genetic: SB-728-T
3 Recruiting A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
4 Recruiting High-dose Cyclophosphamide for Severe Refractory Crohn Disease
Conditions: Crohn's Disease;   Crohn Disease
Intervention: Drug: High-dose Cyclophosphamide
5 Recruiting A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Conditions: Solid Tumors;   Soft-tissue Sarcoma;   Breast Cancer
Interventions: Drug: Cyclophosphamide and JX-594 dose escalation;   Drug: Cyclophosphamide and JX-594;   Drug: Cyclophosphamide
6 Completed
Has Results
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Conditions: Burkitt's Lymphoma;   Lymphoblastic Lymphoma;   Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
7 Recruiting TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Conditions: Adult Solid Neoplasm;   Colorectal Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Colorectal Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Pancreatic Cancer
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Drug: TLR8 Agonist VTX-2337
8 Recruiting Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Veliparib
9 Not yet recruiting Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients
Condition: Recurrent Endometrial Cancer
Interventions: Drug: Olaparib;   Drug: metformin;   Drug: metronomic cyclophosphamide
10 Terminated Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: Alvocidib Hydrochloride;   Drug: Cyclophosphamide;   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
11 Recruiting Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Pharmacological Study
12 Recruiting Ixazomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Condition: Plasma Cell Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
13 Recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
14 Terminated
Has Results
Phase II ABT-888 With Cyclophosphamide
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Serous Carcinoma Cancer;   Triple-Negative Breast Cancer;   Fallopian Tube Cancer
Interventions: Drug: ABT-888;   Drug: Cyclophosphamide
15 Recruiting SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Smac Mimetic LCL161
16 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide
17 Recruiting Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
18 Completed
Has Results
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Conditions: Mantle Cell Lymphoma;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: G-CSF
19 Active, not recruiting Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
Condition: Pemphigus
Intervention: Drug: Rituximab and Cyclophosphamide IV
20 Active, not recruiting Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)
Conditions: Chronic Fatigue Syndrome (CFS);   Myalgic Encephalomyelitis (ME)
Intervention: Drug: Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years